Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.08 USD
Change Today 0.00 / 0.00%
Volume 16.8K
SNWV On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

sanuwave health inc (SNWV) Snapshot

Open
$0.08
Previous Close
$0.08
Day High
$0.08
Day Low
$0.08
52 Week High
06/23/14 - $0.55
52 Week Low
05/7/15 - $0.04
Market Cap
5.3M
Average Volume 10 Days
69.2K
EPS TTM
$-0.08
Shares Outstanding
63.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SANUWAVE HEALTH INC (SNWV)

Related News

No related news articles were found.

sanuwave health inc (SNWV) Related Businessweek News

No Related Businessweek News Found

sanuwave health inc (SNWV) Details

SANUWAVE Health, Inc., a shockwave technology company, focuses on the development and commercialization of noninvasive, high-energy, and acoustic shockwaves for regenerative medicine and other applications. The company’s shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. Its lead product is the demaPACE device, which is in a supplemental Phase III clinical study for treating diabetic foot ulcers. The company’s portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body’s normal healing processes and regeneration. It also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. The company sells its devices and accessories in Europe, Canada, and Asia/Pacific. SANUWAVE Health, Inc. was founded in 2005 and is based in Alpharetta, Georgia.

8 Employees
Last Reported Date: 03/3/15
Founded in 2005

sanuwave health inc (SNWV) Top Compensated Officers

Chairman, Chief Executive Officer, Chairman o...
Total Annual Compensation: $90.0K
Chief Financial Officer and Chief Operating O...
Total Annual Compensation: $245.4K
Compensation as of Fiscal Year 2014.

sanuwave health inc (SNWV) Key Developments

SANUWAVE Health, Inc. Reports Consolidated Unaudited Earnings Results for the First Quarter Ended March 31, 2015

SANUWAVE Health, Inc. reported consolidated unaudited earnings results for the first quarter ended March 31, 2015. Revenues for the three months ended March 31, 2015 were $210,452, compared to $145,098 for the same period in 2014, an increase of $65,354, or 45%. The increase in revenues for 2015 was due to higher sales of orthoPACE® devices in Europe. Research and development expenses for the three months ended March 31, 2015 were $634,623, compared to $764,845 for the same period in 2014, a decrease of $130,222, or 17%.  Net loss for the three months ended March 31, 2015 was $1,159,115, or $0.02 per diluted share, compared to a net loss of $2,563,954, or $0.06 per diluted share, for the same period in 2014, a decrease in the net loss of $1,404,839, or 55%. The decrease in the net loss was primarily a result of reduced operating expenses in 2015. On March 31, 2015, the Company had cash and cash equivalents of $2,454,199 compared with $3,547,071 as of December 31, 2014, a decrease of $1,092,872. For the three months ended March 31, 2015, net cash used by operating activities was $1,080,154, compared to $2,120,800 for the same period in 2014, a decrease of $1,040,646, or 49%. The decrease in cash used by operations was primarily due to the lower operating expenses in 2015 and the reduction of accounts payable and accrued expenses in 2014. Operating loss was $1,126,895 compared to $2,019,799 a year ago. Loss before income taxes was $1,159,115 compared to $2,563,954 a year ago.

SANUWAVE Health, Inc. Provides an Update on the DermaPACE Clinical Trial

SANUWAVE Health, Inc. announced that the independent Data Monitoring Committee (DMC) has performed an interim analysis on the efficacy and safety results in the Phase III supplemental clinical trial using the dermaPACE® for treating diabetic foot ulcers. The DMC performed an analysis of the primary efficacy endpoint of the rate of 100% complete wound closure at the 12-week endpoint for the dermaPACE treated patients as compared to the sham-control patients and the safety data. The DMC has completed its review and noted there were no safety issues. The DMC reported the Monitoring Success Criterion for the primary efficacy endpoint of 100% complete wound closure at 12 weeks has not been met and, assuming similar trends for any additional patents enrolled, will likely not be met at the next predefined analysis point of 170 patients. The Monitoring Success Criterion is a predictive probability of dermaPACE achieving statistical significance in the rate of 100% complete wound closure at 12 weeks as compared to the rate for sham-control. SANUWAVE is actively working with the FDA regarding the data requests from the DMC. The interaction with the FDA will determine if the Company discontinues enrollment and moves to lock the database and unblind the data with the intention of filing a PMA with the FDA in late 2015, or continues the dermaPACE clinical study. The Company expects to have feedback from the FDA by the end of this quarter and will provide an update to shareholders at that time. SANUWAVE retained Musculoskeletal Clinical Regulatory Advisers, LLC (MCRA) in January 2015 to lead the Company's interactions and correspondence with the FDA for the dermaPACE, which have already commenced. MCRA has successfully worked with the FDA on numerous PMAs for various musculoskeletal, restorative and general surgical devices since 2006.

SANUWAVE Health, Inc. to Report Q1, 2015 Results on May 06, 2015

SANUWAVE Health, Inc. announced that they will report Q1, 2015 results at 5:00 PM, Eastern Standard Time on May 06, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SNWV:US $0.08 USD 0.00

SNWV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Derma Sciences Inc $6.56 USD -0.01
Smith & Nephew PLC 1,160 GBp -10.00
View Industry Companies
 

Industry Analysis

SNWV

Industry Average

Valuation SNWV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.8x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANUWAVE HEALTH INC, please visit www.sanuwave.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.